Top Public Companies in Weight Loss
The global weight management market is dominated by a few major players with strong financial results. Eli Lilly leads with its GLP-1 receptor agonist Wegovy, which generated over 6 billion dollars in revenue in the most recent full fiscal year. Novo Nordisk follows closely with Ozempic and Wegovy combined sales, reporting total obesity and diabetes care revenue exceeding 10 billion dollars for the latest reporting period. Both companies have seen stock price surges driven by demand, but they also face supply constraints and regulatory scrutiny. For detailed financials, see the latest SEC filings on Eli Lilly's revenue breakdown and Novo Nordisk's annual results. SEC filings
Market share data from industry reports shows that injectable GLP-1 therapies now account for the majority of prescription weight loss revenue. Analysts project this segment will grow at a compound annual growth rate above 20 percent through the next decade. Companies like Pfizer and Viking Therapeutics are developing oral alternatives that could shift the competitive landscape. The latest clinical trial data and market projections are available in recent coverage from Forbes and other financial news outlets. Forbes coverage
Key Strategies Behind Successful Weight Loss Programs
Effective commercial weight loss programs combine pharmacotherapy with behavioral support and digital tracking. Companies like WW International and Noom use app-based coaching and calorie tracking to complement their products. WW reported a decline in total revenue in the most recent quarter but is focusing on digital subscriptions and partnerships with health insurers. Noom has expanded its platform to include glucose monitoring and personalized meal planning based on user data. SEC filings
Hospital-based medical weight loss centers are also a growing segment, offering supervised very low calorie diets and endoscopic procedures. The American Board of Obesity Medicine certifies physicians who specialize in this field, and the number of certified specialists has increased steadily. Newer entrants are combining FDA-approved medications with continuous glucose monitors and wearable devices to create integrated solutions. These strategies aim to improve long-term adherence and outcomes compared to diet and exercise alone. Forbes health
Regulatory and Safety Landscape
The FDA has approved several prescription drugs for chronic weight management, including semaglutide, liraglutide, phentermine-topiramate, and naltrexone-bupropion. Each approved medication has specific eligibility criteria based on body mass index and weight-related conditions. The agency also monitors compounding pharmacies that produce formulations of these drugs without FDA approval, issuing warnings about safety risks. Recent enforcement actions and guidance documents are publicly available on the FDA website. FDA weight loss
Insurance coverage for weight loss drugs has expanded in 2024, with major payers adding GLP-1 agonists to their formularies for eligible patients. This shift is expected to increase access and drive further revenue growth for manufacturers. However, some insurers have implemented step therapy requirements and quantity limits to manage costs. The impact of these policies on patient outcomes and company earnings is being tracked by analysts and reported in financial media. Forbes